RESUMEN
BACKGROUND: Low adherence to chronic immunosuppression is associated with suboptimal transplantation outcomes. Mobile-health technology is a promising tool to monitor medication adherence, but data on patient engagement to these tools are lacking. METHODS: Prospective, observational, multicenter, 2-phase trial in kidney and liver transplant recipients, investigating the degree of engagement to TrackYourMed® (TYM), a novel m-Health technology with a QR code-scan app to track immunosuppression adherence and its association with drug monitoring. RESULTS: Out of 204 consecutive transplant patients, 90 patients were eligible to participate. 61 (68%) used TYM regularly, 21 (23%) never or barely used it, 5 (5.5%) were irregular users, and 3 (3.3%) were lost to follow-up. 6-month total correct intakes (CIN) ranged between 69%-76%, 12%-19% intakes were out-of-time (OUT), and 9%-12% were missed (MIS). Notably, a rate of intakes out of the scheduled time higher than 20% in the 6 days prior to blood immunosuppressant trough levels was associated with a higher intra-patient variability (17 IQR 13-21% vs. 29 IQR 23%-36%, p = .001), and with a higher dose-adjustment (p < .001). At 1 year, 53(59%) patients were still active users of TYM. CONCLUSIONS: Implementing m-Health technologies promoting immunosuppression adherence may be useful for a relevant number of transplant patients and help transplant physicians identifying erratic immunosuppression adherence.
Asunto(s)
Trasplante de Riñón , Aplicaciones Móviles , Trasplante de Órganos , Telemedicina , Tecnología Biomédica , Humanos , Terapia de Inmunosupresión , Inmunosupresores , Cumplimiento de la Medicación , Proyectos Piloto , Estudios Prospectivos , TecnologíaRESUMEN
Thrombotic thrombocytopenic purpura (TTP) is a low prevalence disease characterized by severe deficiency of the enzyme ADAMTS13, leading to the development of thrombotic microangiopathy (TMA) and often resulting in severe organ disfunction. TTP is an extremely serious condition and, therefore, timely and appropriate treatment is critical to prevent life-threatening complications.Over the past 25 years, significant advances in the understanding of the pathophysiology of immune TTP have led to the development of readily available techniques for measuring ADAMTS13 levels, as well as new drugs that are particularly effective in the acute phase and in preventing relapses. These developments have improved the course of the disease.Given the complexity of the disease and its various clinical and laboratory manifestations, early diagnosis and treatment can be challenging.To address this challenge, a group of experienced professionals from the Catalan TTP group have developed this consensus statement to standardize terminology, diagnosis, treatment and follow up for immune TTP, based on currently available scientific evidence in the field. This guidance document aims to provide healthcare professionals with a comprehensive tool to make more accurate and timely diagnosis of TTP and improve patient outcomes.
Asunto(s)
Púrpura Trombocitopénica Idiopática , Púrpura Trombocitopénica Trombótica , Humanos , Púrpura Trombocitopénica Trombótica/diagnóstico , Púrpura Trombocitopénica Trombótica/terapia , Púrpura Trombocitopénica Trombótica/etiología , Proteína ADAMTS13 , Consenso , Factor de von Willebrand , RecurrenciaRESUMEN
PURPOSE: COVID-19 pandemic has multifaceted presentations with rising evidence of immune-mediated mechanisms underplay. We sought to explore the outcomes of severe COVID-19 patients treated with a multi-mechanism approach (MMA) in addition to standard-of-care (SC) versus patients who only received SC treatment. MATERIALS AND METHODS: Data were collected retrospectively for patients admitted to the intensive care unit (ICU). This observational cohort study was performed at five institutions, 3 in the United States and 2 in Honduras. Patients were stratified for MMA vs. SC treatment during ICU stay. MMA treatment consists of widely available medications started immediately upon hospitalization. These interventions target immunomodulation, anticoagulation, viral suppression, and oxygenation. Primary outcomes included in-hospital mortality and length of stay (LOS) for the index hospitalization and were measured using logistic regression. RESULTS: Of 86 patients admitted, 65 (76%) who had severe COVID-19 were included in the study; 30 (46%) patients were in SC group, compared with 35 (54%) patients treated with MMA group. Twelve (40%) patients in the SC group died, compared with 5 (14%) in the MMA group (p-value = 0.01, Chi squared test). After adjustment for gender, age, treatment group, Q-SOFA score, the MMA group had a mean length of stay 8.15 days, when compared with SC group with 13.55 days. ICU length of stay was reduced by a mean of 5.4 days (adjusted for a mean age of 54 years, p-value 0.03) and up to 9 days (unadjusted for mean age), with no significant reduction in overall adjusted mortality rate, where the strongest predictor of mortality was the use of mechanical ventilation. CONCLUSION: The finding that MMA decreases the average ICU length of stay by 5.4 days and up to 9 days in older patients suggests that implementation of this treatment protocol could allow a healthcare system to manage 60% more COVID-19 patients with the same number of ICU beds.
Asunto(s)
COVID-19/terapia , Unidades de Cuidados Intensivos , Tiempo de Internación , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/epidemiología , Femenino , Honduras/epidemiología , Humanos , Factores Inmunológicos/administración & dosificación , Masculino , Persona de Mediana Edad , Respiración Artificial , Síndrome de Dificultad Respiratoria/terapia , Estudios Retrospectivos , Resultado del Tratamiento , Tratamiento Farmacológico de COVID-19RESUMEN
INTRODUCTION: Excessive bleeding (EB) after cardiopulmonary bypass (CPB) may lead to increased mortality, morbidity, transfusion requirements and re-intervention. Less than 50% of patients undergoing re-intervention exhibit surgical sources of bleeding. We studied clinical and genetic factors associated with EB. METHODS: We performed a nested case-control study of 26 patients who did not receive antifibrinolytic prophylaxis. Variables were collected preoperatively, at intensive care unit (ICU) admission, at 4 and 24 hours post-CPB. EB was defined as 24-hour blood loss of > 1 l post-CPB. Associations of EB with genetic, demographic, and clinical factors were analyzed, using SPSS-12.2 for statistical purposes. RESULTS: EB incidence was 50%, associated with body mass index (BMI) < 26.4 (25-28) Kg/m2, (P = 0.03), lower preoperative levels of plasminogen activator inhibitor-1 (PAI-1) (P = 0.01), lower body temperature during CPB (P = 0.037) and at ICU admission (P = 0.029), and internal mammary artery graft (P = 0.03) in bypass surgery. We found a significant association between EB and 5G homozygotes for PAI-1, after adjusting for BMI (F = 6.07; P = 0.02) and temperature during CPB (F = 8.84; P = 0.007). EB patients showed higher consumption of complement, coagulation, fibrinolysis and hemoderivatives, with significantly lower leptin levels at all postoperative time points (P = 0.01, P < 0.01 and P < 0.01). CONCLUSION: Excessive postoperative bleeding in CPB patients was associated with demographics, particularly less pronounced BMI, and surgical factors together with serine protease activation.
Asunto(s)
Puente Cardiopulmonar/efectos adversos , Mortalidad Hospitalaria/tendencias , Hemorragia Posoperatoria/diagnóstico , Hemorragia Posoperatoria/mortalidad , Adulto , Anciano , Análisis Químico de la Sangre , Coagulación Sanguínea/fisiología , Puente Cardiopulmonar/métodos , Estudios de Casos y Controles , Complemento C3/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Fibrinólisis/fisiología , Estudios de Seguimiento , Humanos , Unidades de Cuidados Intensivos , Leptina/sangre , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Inhibidor 1 de Activador Plasminogénico/metabolismo , Cuidados Posoperatorios , Hemorragia Posoperatoria/terapia , Cuidados Preoperatorios , Probabilidad , Medición de Riesgo , Índice de Severidad de la Enfermedad , Estadísticas no Paramétricas , Análisis de SupervivenciaRESUMEN
El campo de acción en que se desarrolla el cirujano dentista no debe restringirse al trabajo habitual del consultorio, sino que debe formar parte de un equipo médico en donde su colaboración con otros especialistas sea de apoyo terapéutico y diagnóstico en padecimientos tanto bucales como sistémicos. El presente trabajo consistió en efectuar una revisión de la literatura relacionada con los usos diagnósticos de la saliva. Asimismo, se reportan dos casos de mujeres sometidas a hiperestimulación ovárica, a quienes se les efectuaron determinaciones seriadas de estradiol sérico y salival simultáneamente, encontrándose un alto grado de efectividad y confiabilidad del uso de la saliva como un medio no invasivo para efectuar procedimientos diagnósticos de utilidad práctica no solo para el odontólogo, sino para el médico en general
Asunto(s)
Humanos , Femenino , Diagnóstico , Diagnóstico Bucal , Enfermedades de la Boca/diagnóstico , Saliva/fisiología , Enfermedades del Sistema Endocrino/diagnósticoRESUMEN
El presente trabajo constituye la experiencia obtenida de la aplicación del psicoballet como actividad terapéutica con un grupo de niños. Las edades están comprendidas entre cuatro y seis años, siendo el grupo heterogéneo en diagnóstico y homogéneo en sexo (varones). El ciclo de tratamiento tuvo una duración de cuatro meses, desarrollando las sesiones terapéuticas una vez por semana. El método fue utilizado de acuerdo a las normas de trabajo del psicoballet del Hospital Psiquiátrico de la Habana (HPH), de donde recibimos todo el asesoramiento técnico y metodológico que posibilitó el desarrollo exitoso del trabajo